(Q37346073)

19 August 2017

0 references

Antitumor activity of nivolumab on hemodialysis after renal allograft rejection (English)

1 reference

19 August 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

Samuel Bourassa-Blanchette

3 June 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Greg Knoll

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

4

Christina Canil

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Andrea Marie Ibrahim

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Todd Fairhead

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

18 October 2016

1 reference

Journal for Immunotherapy of Cancer

19 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients

3 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Post-transplantation malignancies: here today, gone tomorrow?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Pembrolizumab versus Ipilimumab in Advanced Melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Systematic review of melanoma incidence and prognosis in solid organ transplant recipients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Role of the PD-1 pathway in the immune response

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Cancer incidence and risk factors after solid organ transplantation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Skin cancers after organ transplantation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Belatacept and Long-Term Outcomes in Kidney Transplantation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

[Management of targeted therapies in hemodialysis patients].

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5067882

Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27777773

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27777773

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S40425-016-0171-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27777773%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

PubMed publication ID

27777773

1 reference